- Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
- Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
- Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
- Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference
- Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
- Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings
- Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
- Prime Medicine to Participate in Upcoming Investor Conferences
- Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
- Prime Medicine Announces Pricing of Upsized Public Offering
More ▼
Key statistics
On Wednesday, Prime Medicine Inc (PRME:NMQ) closed at 7.45, 81.27% above the 52 week low of 4.11 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.08 |
---|---|
High | 8.12 |
Low | 7.42 |
Bid | 7.50 |
Offer | 7.77 |
Previous close | 7.45 |
Average volume | 919.44k |
---|---|
Shares outstanding | 120.03m |
Free float | 88.25m |
P/E (TTM) | -- |
Market cap | 894.23m USD |
EPS (TTM) | -2.17 USD |
Data delayed at least 15 minutes, as of May 22 2024 21:00 BST.
More ▼